Related Experiment Video

Updated: Aug 7, 2026

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

Bisphosphonate induces apoptosis and inhibits pro-osteoclastic gene expression in prostate cancer cells

Hideki Asahi1, Atsushi Mizokami, Sotaro Miwa

  • 1Department of Urology, School of Medicine, Kanazawa University, Kanazawa, Japan.

International Journal of Urology : Official Journal of the Japanese Urological Association
|June 15, 2006
PubMed
Abstract

Insights

Minodronate, a bisphosphonate, inhibits prostate cancer cell growth by inducing apoptosis and reducing pro-osteoclastic gene expression. This suggests a direct anti-cancer effect beyond managing skeletal complications.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Bisphosphonates are standard for managing cancer-induced skeletal issues.
  • Emerging evidence suggests bisphosphonates induce apoptosis in cancer cells and osteoclasts at bone metastatic sites.

Purpose of the Study:

  • To investigate the direct impact of minodronate on prostate cancer.
  • To assess minodronate's effects on prostate cancer cell proliferation and apoptosis-related protein expression.

Main Methods:

  • Prostate cancer cell lines (PC-3, DU145, LNCaP) were treated with minodronate.
  • Assessed were cell proliferation, apoptosis, and expression of key proteins (bcl-2, bax, PARP, caspase-3) and factors (RANKL, OPG, MMP-2, PTHrP).

Main Results:

  • Minodronate significantly inhibited prostate cancer cell proliferation.
  • Observed were DNA fragmentation and TUNEL-positive nuclei in treated cells.
  • Minodronate modulated apoptosis markers (decreased bcl-2, increased bax, caspase-3 activity, PARP degradation) and reduced pro-osteoclastic factors (RANKL, PTHrP, MMP-2).

Conclusions:

  • Minodronate directly promotes apoptosis in prostate cancer cells.
  • Minodronate decreases the expression of genes that promote osteoclast activity in prostate cancer cells.

More Related Videos

Osteoclast Derivation from Mouse Bone Marrow06:17

Osteoclast Derivation from Mouse Bone Marrow

Published on: November 6, 2014

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...